𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate

✍ Scribed by Jaspreet Pannu; Yoshihide Asano; Sashidhar Nakerakanti; Edwin Smith; Stefania Jablonska; Maria Blaszczyk; Peter ten Dijke; Maria Trojanowska

Book ID
102752508
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
634 KB
Volume
58
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Is imatinib mesylate a promising drug in
Is imatinib mesylate a promising drug in systemic sclerosis?
✍ P. L. A. van Daele; W. A. Dik; H. B. Thio; P. Th. W. van Hal; J. A. M. van Laar; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 114 KB

## Abstract A patient with therapy‐resistant and progressive systemic sclerosis (SSc) with pulmonary involvement who was treated with imatinib mesylate is described herein. Prior to treatment, pulmonary fibroblasts obtained from the patient were cultured and incubated with imatinib mesylate. Preinc